Departamento de Clínica Médica, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, SP Brazil.
Genet Mol Biol. 2009 Oct;32(4):709-11. doi: 10.1590/S1415-47572009005000067. Epub 2009 Dec 1.
Exposure to benzene has been associated with haematological diseases such as neutropenia (NEB) and acute myeloid leukaemia (AML). We tested whether the null genotypes of the GSTM1 and GSTT1 genes, involved in benzene inactivation, altered the risk for NEB in southeastern Brazil. Genomic DNA from 55 NEB patients and 330 controls was analysed by multiplex-polymerase chain reaction. The frequency of the GSTM1, GSTT1 and combined null genotypes was similar in patients and controls (GSTM1, 27.3% vs. 38.8%, p = 0.16; GSTT1, 25.5% vs. 19.7%, p = 0.24; GSTM1/GSTT1, 12.7% vs. 6.7%, p = 0.26; respectively). The distribution of genotype classes in NEB patients was similar to normal controls, suggesting that GSTM1 and GSTT1 null genotypes make no specific contribution to the risk of NEB. As the GSTM1 and GSTT1 null genotypes were previously associated with increased risk for AML in Brazil and elsewhere, we hypothesise that different thresholds of chemical exposure relative to distinct GSTM1 and GSTT1 genotypes may determine whether AML or NEB manifests in benzene exposed individuals from southeastern Brazil. Although indicative, our results still require support by prospective and large scale epidemiological studies, with rigorous assessment of daily chemical exposures and control of the possible contribution of other polymorphic genes involved in benzene metabolism.
苯暴露与血液疾病有关,如中性粒细胞减少症(NEB)和急性髓系白血病(AML)。我们测试了参与苯失活的 GSTM1 和 GSTT1 基因的无效基因型是否改变了巴西东南部 NEB 的风险。通过多重聚合酶链反应分析了 55 名 NEB 患者和 330 名对照的基因组 DNA。患者和对照组的 GSTM1、GSTT1 和联合无效基因型的频率相似(GSTM1,27.3%对 38.8%,p=0.16;GSTT1,25.5%对 19.7%,p=0.24;GSTM1/GSTT1,12.7%对 6.7%,p=0.26;分别)。NEB 患者的基因型分类分布与正常对照相似,表明 GSTM1 和 GSTT1 无效基因型对 NEB 风险没有特殊贡献。由于 GSTM1 和 GSTT1 无效基因型先前与巴西和其他地区 AML 风险增加有关,我们假设相对于不同的 GSTM1 和 GSTT1 基因型,化学暴露的不同阈值可能决定在巴西东南部暴露于苯的个体中是否会出现 AML 或 NEB。尽管具有指示性,但我们的结果仍需要前瞻性和大规模的流行病学研究的支持,需要严格评估每日化学暴露,并控制参与苯代谢的其他多态性基因的可能贡献。